(Q56985000)

English

Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients

article by Gero Tenderich et al published July 2007 in Clinical Transplantation

In more languages

Statements

scholarly article

0 references

Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients (English)

0 references

1 reference

based on heuristic

inferred from title

Rebecca Muckelbauer

object named as

Rebecca Muckelbauer

4

0 references

Armin Zittermann

3

object named as

Armin Zittermann

0 references

author name string

Gero Tenderich

1

0 references

Uwe Fuchs

2

0 references

Heiner K. Berthold

5

0 references

Reiner Koerfer

6

0 references

publication date

July 2007

0 references

Clinical Transplantation

0 references

21

0 references

4

0 references

536-543

0 references

Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report--2005.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Chronic renal failure after transplantation of a nonrenal organ

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Role of siroliumus, a novel immunosuppressive drug in heart and lung transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Review of the proliferation inhibitor everolimus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Cardiac allograft vasculopathy: pathology, prevention and treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Rapamycin: clinical results and future opportunities

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Lipid metabolism in renal transplant patients receiving tacrolimus/sirolimus combination therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Strategies for minimizing hyperlipidemia after cardiac transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Comparison of statins in hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Pharmacologic treatment expectations in the management of dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2007.00686.X

21 January 2018

Identifiers

10.1111/J.1399-0012.2007.00686.X

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56985000&oldid=1783604242"